Terlipressin
Title: Terlipressin
CAS Registry Number: 14636-12-5
CAS Name: N-[N-(N-Glycylglycyl)glycyl]-8-L-lysinevasopressin
Additional Names: Na-glycylglycylglycylvasopressin; 1-triglycyl-8-lysinevasopressin
Trademarks: Glypressin (Ferring)
Molecular Formula: C52H74N16O15S2
Molecular Weight: 1227.37
Percent Composition: C 50.89%, H 6.08%, N 18.26%, O 19.55%, S 5.22%
Literature References: Analog of lypressin, q.v. Prepn: E. Kasafirek et al., Collect. Czech. Chem. Commun. 31, 4581 (1966); Z. Procházka et al., ibid. 43, 1285 (1978). Pharmacological studies: J. Kyncl et al., Eur. J. Pharmacol. 28, 294 (1974); P. O. B. Sjöquist et al., Acta Pharmacol. Toxicol. 40, 369 (1977). Use in treatment of uterine bleeding: V. Pavlin et al., Br. J. Obstet. Gynaecol. 85, 801 (1978). Hemostatic effects in cirrhosis patients: C. V. Prowse et al., Eur. J. Clin. Invest. 10, 49 (1980). Conversion to lysine vasopressin in man: M. L. Forsling et al., J. Endocrinol. 85, 237 (1980). Uterine effects in first trimester of pregnancy: T. Laudanski, M. Aakerlund, Contraception 22, 199 (1980). Single-dose effects on renal potassium excretion in humans: H. Nadvornikova, O. Schueck, Int. J. Clin. Pharmacol. Ther. Toxicol. 20, 155 (1982).
 
Derivative Type: Diacetate pentahydrate
Trademarks: Glycylpressin (Ferring)
Molecular Formula: C56H82N16O19S2.5H2O
Molecular Weight: 1437.55
Percent Composition: C 46.79%, H 6.45%, N 15.59%, O 26.71%, S 4.46%
Properties: [a]D25 -82° (c = 0.2 in 1M acetic acid).
Optical Rotation: [a]D25 -82° (c = 0.2 in 1M acetic acid)
 
Therap-Cat: Vasopressor (treatment of uterine and esophogeal bleeding).
Keywords: Antidiuretic.

Others monographs:
Platinic ChlorideSeaborgiumDiethylacetic AcidPropyzamide
PiperonalAcetyl BromideRibostamycinp-Toluenesulfonyl Chloride
L-ErythroseCephradine1,2-BenzanthraceneTocainide
Pamoic AcidReserpineMagnesium StannideCiticoline
©2016 DrugLead US FDA&EMEA